Please login to the form below
cell therapies
This page shows the latest cell therapies news and features for those working in and with pharma, biotech and healthcare.
MedCity sets up advanced therapy research network
The UK’s life sciences hub MedCity has launched an initiative to foster greater collaboration between industry and academia in cell, tissue and gene therapies. ... The government-funded Cell and Gene Therapy Catapult is currently building a £55m
Latest news
-
Soon-Shiong presents first data on cancer memory vaccine at SITC
According to Soon-Shiong, that approach should overcome the limitations of checkpoint inhibitor monotherapy, which only works in a proportion of patients, as well as cell-based CAR-T therapies that ... Patrick Soon-Shiong. In the prostate cancer trial,
-
Novartis: pipeline will generate 60 filings in three years
Novartis is showcasing its R&D pipeline at an event in London today, pledging to make no fewer than 60 'major' submissions from 2019 to 2021 across its drug, cell and ... Advanced therapy medicinal products. Novartis’push into advanced therapy
-
Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts
Kite was sold on to Gilead Sciences, along with FDA-approved CAR-T therapy Yescarta, one of the first two of the groundbreaking cell therapies to reach the market, just behind ... allogeneic cell therapy and the potential for greater and faster patient
-
Novartis cuts manufacturing jobs in Switzerland and UK
This reflects the move away from simpler small molecule-based pills towards a greater reliance on biologics and the new and highly complex manufacturing required for cell therapies, such as ... The company says it has already invested more than $1bn in
-
CHMP backs Spark’s Luxturna, but rejects Sarepta again
Once approved, Luxturna will be sold in Europe by Novartis, which has been steadily building a portfolio of cell and gene therapies in the last couple of years through licensing deals. ... therapies. The CHMP turned down Sarepta’s application for
More from news
Approximately 2 fully matching, plus 96 partially matching documents found.
Latest Intelligence
-
Making Europe a leader in bioscience: boosting trust and opening minds
New disruptive innovation is changing the way we create value in healthcare: big data, artificial intelligence, the growing role of patients, the discovery of new materials and biologics, gene, cell and ... This involves incorporating new diagnostic
-
Cancer immunotherapy: What's on the horizon?
Between November 2016 and October 2017, the FDA approved 31 new therapies for more than 16 types of tumour, including the first cell-based therapies, the first tumour-agnostic drugs and ... cell-based therapies and oncolytic viruses that attack malignant
-
Bluebird Bio: on the cusp of a gene therapy revolution
class gene or cell therapies by 2022. ... Cell and gene therapies undoubtedly do pose difficult questions – but there is also no question of holding back because of this business model uncertainty.
-
No incentive for a cure
Cell and gene therapies in particular are heralding remarkable curative medicines, which are given only once, or over the short term. ... Healthcare systems are currently set up to cover moderate costs for chronic therapies over a medium to longer period
-
The good, the bad and the ugly
The oncology market is certainly evolving. “Some of the most interesting play is in immuno-oncology, where combination therapies are increasingly being explored. ... It will also be interesting to see how gene therapies and cell-based therapies, like
More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest appointments
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult, Filippo Petti joins Ceylad and Vivienne Fox to chair RFI
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
-
Industry appointments
Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand
-
Abeona Therapeutics appoints new additions to board of directors
Abeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the appointment of Stefano Buono and Richard Van Duyne. ... He said: “Abeona’s ambitious gene
-
Turnstone Biologics bolsters leadership team
Prior to his new role, he was chief business officer at SQZ Biotech, a clinical-stage group focusing on developing cell therapies.
-
Avita Medical appoints CEO
chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... Prior to Novartis Perry was global head of R&D for the bioscience division at Baxter Healthcare, vice president of
More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest from PMHub
-
Animal Auto-Immune Disease Therapeutics Market to Register a Steady Growth by 2026
There are several ways of treating the auto immune diseases in animals using various drugs and other therapies like surgeries and stem cell therapies.
-
Leukemia Therapeutics Treatment Market Revenue, Opportunity, Segment and Key Trends 2015 - 2025
Leukemia is defined as a cancer observed in white blood cell (WBC) in our body. ... White blood cell helps our body to fight against infection caused by harmful pathogen.
-
Stem Cell Therapies Market Expected to Dominate Worldwide by 2025
Stem Cell Therapies Market Expected to Dominate Worldwide by 2025. Future Market Insights has announced the addition of the “ Stem Cell Therapies Market: Global Industry Analysis and Opportunity Assessment 2015 - 2025"
-
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Meet the CEO behind ReNeuron’ s cutting-edge stem cell therapies. Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’ s latest innovation in ... The biotech creates ‘ off-the-shelf’ cell-based therapies,
-
Introduction to the manufacturing of biologics
However, the broad definition of a biologic is they are created by either a microorganism or a mammalian cell, and are large, complex molecules; the majority of which are proteins ... include blood or blood products, gene therapies, vaccines, and cell
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
Featured jobs
- Account Manager- Healthcare Advertising
-
Negotiable
-
Systematic Reviewer - Oxford
-
Negotiable
- Principal Health Economist - North-West
-
Negotiable
-
Business Director
-
Competitive Salary Offered
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Account Manager- Healthcare Advertising
-
Negotiable
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
-
Medical (Scientific) Director
-
£120, 000 benefits
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Manager
-
Negotiable
-
Account Director
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
Subscribe to our email news alerts
- Industry frustrated by late warning on 'no deal' Brexit disruption
- UK’s genomics leadership attracts IQVIA investment, regardless of Brexit
- Lucid Group celebrate another magical year at their Winter Meeting
- Biogen picks up another drug from wide-ranging Ionis alliance
- As France protests, Sanofi takes axe to 670 jobs
- Leicester NHS Trust’s staff intranet is integral to HCPs’ working day
PMHub
GK Strategy
GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....
Latest intelligence
- Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
- What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
- What everyone forgets about good organisational change in pharma
- Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
- Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
- Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...
Quick links
Infographics
